Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12226620 | 0.92 | MEN1 (0.46) | DRD2SIGMAR1MEN1KMT2AADRA1A | |
| SCHEMBL917838 | 0.78 | OPRM1 (0.50) | ADRA1AGAAKCNA3 | |
| SCHEMBL918200 | 0.78 | OPRM1 (0.63) | ADRA1ACCR1 | |
| SCHEMBL917869 | 0.73 | KCNH2 (0.67) | DRD2SIGMAR1DRD3 | |
| SCHEMBL13255330 | 0.72 | CCR3 (0.59) | SIGMAR1 | |
| SCHEMBL918100 | 0.70 | CCR3 (0.63) | SIGMAR1 | |
| SCHEMBL12111422 | 0.70 | OPRM1 (0.52) | KMT2AADRA1A | |
| SCHEMBL918595 | 0.69 | CCR1 (0.65) | DRD2ADRA1ADRD3CCR1 | |
| SCHEMBL12250372 | 0.69 | OPRM1 (0.59) | ADRA1A | |
| SCHEMBL917905 | 0.69 | DRD2 (0.57) | DRD2SIGMAR1MEN1KMT2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-8642801-B2 | Methods and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-02-04 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-20110021813-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | KONG XIANQI | 2011-01-27 | — | — | US | disclosed |
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-05-06 | — | — | US | disclosed |
| US-7414076-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-08-19 | — | — | US | disclosed |
| US-20080027097-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-01-31 | — | — | US | disclosed |
| US-7253306-B2 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-08-07 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021813-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | MPST, TTR, STS | DRD2 3041/4885SIGMAR1 3298/4885MEN1 1137/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | DRD2 4826/4885SIGMAR1 3888/4885MEN1 1011/4885 |
| US-20080027097-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | MPST, TTR, STS | DRD2 3041/4885SIGMAR1 3298/4885MEN1 1137/4885 |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | DRD2 4826/4885SIGMAR1 3888/4885MEN1 1011/4885 |
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | DRD2 4826/4885SIGMAR1 3888/4885MEN1 1011/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | DRD2 4762/4885SIGMAR1 3877/4885MEN1 683/4885 |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | DRD2 4826/4885SIGMAR1 3888/4885MEN1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.